Andrew Polovin Sells 8,703 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 8,703 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the sale, the executive vice president directly owned 128,215 shares of the company’s stock, valued at $5,650,435.05. This represents a 6.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Friday, February 20th, Andrew Polovin sold 10,949 shares of Tempus AI stock. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19.

Tempus AI Stock Performance

Tempus AI stock opened at $46.18 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The company has a market capitalization of $8.29 billion, a PE ratio of -26.85 and a beta of 3.99. The firm has a fifty day simple moving average of $48.89 and a two-hundred day simple moving average of $59.29. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. During the same quarter in the previous year, the company earned ($0.24) earnings per share. The company’s revenue for the quarter was up 36.1% compared to the same quarter last year. Research analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current year.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. increased its position in shares of Tempus AI by 1.5% during the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after buying an additional 162 shares during the period. US Bancorp DE increased its position in shares of Tempus AI by 6.6% during the third quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after buying an additional 176 shares during the period. Legacy Bridge LLC increased its position in shares of Tempus AI by 1.6% during the fourth quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock valued at $733,000 after buying an additional 193 shares during the period. Truist Financial Corp increased its position in shares of Tempus AI by 5.8% during the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after buying an additional 194 shares during the period. Finally, Farther Finance Advisors LLC increased its position in shares of Tempus AI by 3.5% during the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock valued at $377,000 after buying an additional 219 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Jefferies Financial Group assumed coverage on shares of Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective on the stock. Robert W. Baird assumed coverage on shares of Tempus AI in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Wednesday, March 11th. Finally, Stifel Nicolaus set a $60.00 price objective on shares of Tempus AI in a research report on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Tempus AI has an average rating of “Moderate Buy” and a consensus target price of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.